Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients

被引：20

作者：

Zwaginga, Jaap J. ^{[1
,2
]}

van der Holt, Bronno ^{[3
]}

te Boekhorst, Peter A. ^{[5
]}

Biemond, Bart J. ^{[4
]}

Levin, Mark-David ^{[6
]}

van der Griend, Rene ^{[9
]}

Brand, Anneke ^{[1
,2
]}

Zweegman, Sonja ^{[8
]}

Pruijt, Hans F. M. ^{[10
]}

Novotny, Vera M. J. ^{[13
]}

Vreugdenhil, Art ^{[7
]}

de Groot, Marco R. ^{[14
]}

de Weerdt, Okke ^{[11
,21
]}

van Pampus, Elisabeth C. M. ^{[12
]}

van Maanen-Lamme, Tanja M. ^{[15
]}

Wittebol, Shulamiet ^{[16
]}

Schipperus, Martin R. ^{[17
]}

Silbermann, Matthijs H. ^{[18
]}

Huijgens, Peter C. ^{[8
]}

Luten, Marleen ^{[3
]}

Hollestein, Rene ^{[3
]}

Brakenhoff, Jan A. C. ^{[19
]}

Schrama, Jolanda G. ^{[20
]}

Valster, Fransje A. A. ^{[21
]}

Velders, Gerjo A. ^{[22
]}

Koene, Harry R. ^{[11
,21
]}

机构：

[1] Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, NL-2300 RA Leiden, Netherlands

[2] Leiden Univ, Med Ctr, Sanquin, Jon J van Rood Ctr Clin Transfus Res, NL-2300 RA Leiden, Netherlands

[3] Erasmus MC, Inst Canc, Clin Trial Ctr, HOVON Data Ctr, Rotterdam, Netherlands

[4] Acad Med Ctr Amsterdam, Dept Hematol, Amsterdam, Netherlands

[5] Erasmus MC, Dept Hematol, Rotterdam, Netherlands

[6] Albert Schweitzer Hosp, Dept Internal Med, Dordrecht, Netherlands

[7] Maxima Med Ctr, Dept Internal Med, Veldhoven, Netherlands

[8] Vrije Univ Amsterdam, Med Ctr, Dept Hematol, Amsterdam, Netherlands

[9] Diakonessen Hosp, Dept Internal Med, Utrecht, Netherlands

[10] Jeroen Bosch Hosp, Dept Internal Med, Den Bosch, Netherlands

[11] St Antonius Hosp, Dept Internal Med, Nieuwegein, Netherlands

[12] Radboud Univ Nijmegen, Med Ctr, Dept Lab Med, NL-6525 ED Nijmegen, Netherlands

[13] Radboud Univ Nijmegen, Med Ctr, Dept Hematol, NL-6525 ED Nijmegen, Netherlands

[14] Med Spectrum Twente, Dept Internal Med, Enschede, Netherlands

[15] Westfriesgasthuis, Dept Internal Med, Hoorn, Netherlands

[16] Meander Hosp, Dept Internal Med, Amersfoort, Netherlands

[17] HagaZiekenhuis, Dept Internal Med, The Hague, Netherlands

[18] Tergooiziekenhuizen, Dept Internal Med, Blaricum, Netherlands

[19] Waterland Hosp, Purmerend, Netherlands

[20] Spaarne Hosp, Dept Internal Med, Hoofddorp, Netherlands

[21] Lievensberg Hosp, Dept Internal Med, Bergen Op Zoom, Netherlands

[22] Gelderse Vallei Hosp, Dept Internal Med, Ede, Netherlands

来源：

HAEMATOLOGICA | 2015年 / 100卷 / 03期

关键词：

immune thrombocytopenia; rituximab; splenectomy delaying; early response; open label phase II; ADULT PATIENTS; PURPURA; SPLENECTOMY; THERAPY; EFFICACY; SAFETY; CHILDREN;

D O I：

10.3324/haematol.2014.110213

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E90 / E92

页数：3

共 50 条

[1] A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia
Arnold, Donald M.
Heddle, Nancy M.
Carruthers, Julie
Cook, Deborah J.
Crowther, Mark A.
Meyer, Ralph M.
Liu, Yang
Cook, Richard J.
McLeod, Anne
MacEachern, Janet A.
Mangel, Joy
Anderson, David
Vickars, Linda
Tinmouth, Alan
Schuh, Andre C.
Kelton, John G.
BLOOD, 2012, 119 (06) : 1356 - 1362
[2] Safety and efficacy of hetrombopag in patients with chronic immune thrombocytopenia: a single-arm, open-label, multi-center phase 1 study
Mei, Heng
Chen, Xiequn
Zhou, Jianfeng
Luo, Jianmin
Shi, Qingzhi
Liu, Jing
Wu, Depei
Chen, Guoan
Tai, Yanfei
Xiong, Junye
Zou, Jianjun
Hu, Yu
ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (02)
[3] Intravenous immunoglobulin for maintenance treatment of multifocal motor neuropathy: A multi-center, open-label, 52-week phase 3 trial
Kuwabara, Satoshi
Misawa, Sonoko
Mori, Masahiro
Iwai, Yuta
Ochi, Kazuhide
Suzuki, Hidekazu
Nodera, Hiroyuki
Tamaoka, Akira
Iijima, Masahiro
Toda, Tatsushi
Yoshikawa, Hiroo
Kanda, Takashi
Sakamoto, Ko
Kusunoki, Susumu
Sobue, Gen
Kaji, Ryuji
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2018, 23 (02) : 115 - 119
[4] A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera®) in patients with CD20-positive B-cell non-Hodgkin lymphoma
Han, Xiaohong
Zhang, Mingzhi
Wang, Huaqing
Zhang, Qingyuan
Li, Wei
Hao, Miaowang
Gao, Yuhuan
Jin, Jie
Ren, Hanyun
Tang, Yun
Hong, Xiaonan
Ke, Xiaoyan
Su, Hang
Gui, Lin
Luo, Jianmin
Xie, Liangzhi
Gai, Wenlin
Shi, Yuankai
CHINESE JOURNAL OF CANCER RESEARCH, 2022, 34 (06) : 601 - 611
[5] Safety and efficacy of ciprofol vs. propofol for sedation in intensive care unit patients with mechanical ventilation: a multi-center, open label, randomized, phase 2 trial
Liu, Yongjun
Yu, Xiangyou
Zhu, Duming
Zeng, Jun
Lin, Qinhan
Zang, Bin
Chen, Chuanxi
Liu, Ning
Liu, Xiao
Gao, Wei
Guan, Xiangdong
CHINESE MEDICAL JOURNAL, 2022, 135 (09) : 1043 - 1051
[6] Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study
Jeong, Jae Yoon
Jun, Dae Won
Park, Sol Ji
Sohn, Joo Hyun
Kim, Sang Gyune
Lee, Se Whan
Jeong, Soung Won
Kim, Moon Young
Kim, Won
Shim, Jae-Jun
Kim, Hyoung Su
Suk, Ki Tae
Ahn, Sang Bong
KOREAN JOURNAL OF INTERNAL MEDICINE, 2020, 35 (05) : 1074 - 1083
[7] Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial
Shirasugi, Yukari
Ando, Kiyoshi
Miyazaki, Koji
Tomiyama, Yoshiaki
Okamoto, Shinichiro
Kurokawa, Mineo
Kirito, Keita
Yonemura, Yuji
Mori, Shinichiro
Usuki, Kensuke
Iwato, Koji
Hashino, Satoshi
Wei, Helen
Lizambri, Richard
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2011, 94 (01) : 71 - 80
[8] Does Early Postsurgical Temozolomide Plus Concomitant Radiochemotherapy Regimen Have Any Benefit in Newly-diagnosed Glioblastoma Patients A Multi-center, Randomized, Parallel, Open-label, Phase II Clinical Trial
Mao, Ying
Yao, Yu
Zhang, Li-Wei
Lu, Yi-Cheng
Chen, Zhong-Ping
Zhang, Jian-Min
Qi, Song-Tao
You, Chao
Wang, Ren-Zhi
Yang, Shu-Yuan
Zhang, Xiang
Wang, Ji-Sheng
Chen, Ju-Xiang
Yang, Qun-Ying
Shen, Hong
Li, Zhi-Yong
Wang, Xiang
Ma, Wen-Bin
Yang, Xue-Jun
Zhen, Hai-Ning
Zhou, Liang-Fu
CHINESE MEDICAL JOURNAL, 2015, 128 (20) : 2751 - 2758
[9] Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial
Feng, Fei-Er
Feng, Ru
Wang, Min
Zhang, Jia-Min
Jiang, Hao
Jiang, Qian
Lu, Jin
Liu, Hui
Peng, Jun
Hou, Ming
Shen, Jian-Liang
Wang, Jing-Wen
Xu, Lan-Ping
Liu, Kai-Yan
Huang, Xiao-Jun
Zhang, Xiao-Hui
LANCET HAEMATOLOGY, 2017, 4 (10): : E487 - E496
[10] An open-label, randomized and multi-center clinical trial to evaluate the efficacy of Silibinin in preventing drug-induced liver injury
Gu, Jin
Tang, Shen-Jie
Tan, Shou-Yong
Wu, Qi
Zhang, Xia
Liu, Cun-Xu
Gao, Xu-Sheng
Yuan, Bao-Dong
Han, Li-Jun
Gao, Ai-Ping
Wu, Mei-Ying
Huang, Li-Hua
Ma, Jun
Xiao, He-Ping
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (03): : 4320 - 4327

← 1 2 3 4 5 →